Related Experiment Video
Updated: May 10, 2026

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane
Published on: December 9, 2022
Flavonoids for treating venous leg ulcers
Christopher Scallon1, Sally E M Bell-Syer, Zoriah Aziz
1Epsom, UK. chris.scallon@hotmail.co.uk.
Insights
Flavonoids may aid venous leg ulcer healing, but evidence quality is low. More rigorous trials are needed to confirm the benefits of Micronised Purified Flavonoid Fraction (MPFF) and hydroxyethylrutosides (HR) for chronic wound care.
Area of Science:
- Vascular Medicine
- Dermatology
- Pharmacology
Background:
- Venous leg ulcers represent a significant health burden, costing the UK's NHS approximately GBP 400 million annually.
- Flavonoids, natural venotonic compounds, influence microcirculatory parameters relevant to venous leg ulcer pathophysiology.
Purpose of the Study:
- To systematically evaluate the clinical effectiveness of flavonoid compounds in promoting the healing of venous leg ulcers.
Main Methods:
- A comprehensive literature search was conducted in February 2013 across multiple databases, including Cochrane Wounds, CENTRAL, MEDLINE, EMBASE, and CINAHL.
- Included were randomized controlled trials (RCTs) assessing flavonoid efficacy in adult venous leg ulcer healing, with no date or language restrictions.
- Risk of bias assessment and data extraction were performed independently by two reviewers, with discrepancies resolved by a third author.
Main Results:
- Five trials (723 participants) using Micronised Purified Flavonoid Fraction (MPFF) showed a potential benefit in ulcer healing (RR 1.36), though the most rigorous trial found no significant effect (RR 0.94).
- Four trials (279 participants) on hydroxyethylrutosides (HR) indicated a statistically significant improvement in healed ulcers (RR 1.70).
- The overall quality of reporting for most trials was poor, with an unclear risk of bias, and potential for publication bias was noted.
Conclusions:
- While aggregated data suggest flavonoids (MPFF and HR) may promote venous leg ulcer healing, these findings must be interpreted cautiously due to the poor quality and high risk of bias in most included studies.
- The potential for publication bias further complicates the interpretation of the overall results.
- Further high-quality, rigorously conducted RCTs are necessary to definitively establish the efficacy of flavonoids in venous leg ulcer treatment.
Background:
Venous leg ulcers are a major health burden: annually, in the UK alone, they contribute an estimated cost to the NHS of GBP 400 million. Flavonoids are a diverse group of naturally-occurring venotonic compounds that address certain microcirculatory parameters involved in venous leg ulcer pathophysiology.
Objectives:
To evaluate the clinical effects of flavonoids on the healing of venous leg ulcers.
Search Methods:
In February 2013 we searched the Cochrane Wounds Group Specialised Register; The Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2013, Issue 1); Ovid MEDLINE; Ovid MEDLINE (In-Process & Other Non-Indexed Citations); Ovid EMBASE; and EBSCO CINAHL. No date or language restrictions were applied. We checked reference lists of included trials, and contacted pharmaceutical companies.
Selection Criteria:
Randomised controlled trials (RCTs) that investigated the efficacy of any flavonoid-containing compound on venous leg ulcer healing in adults.
Data Collection And Analysis:
Two review authors independently assessed trials for the review and disagreements were referred to a third author. All rejected articles were double-checked by a third author. Assessment of risk of bias and data extraction were performed independently by two authors, discrepancies were resolved by referring to the third author.
Main Results:
Of the nine studies (1075 participants): five investigated Micronised Purified Flavonoid Fraction (MPFF), and four investigated hydroxyethylrutosides (HR).Meta-analysis involving 723 participants from five trials - four of which were characterised by poor reporting - showed more venous leg ulcers were healed in the MPFF groups than in the control groups (RR 1.36; 95% CI 1.07 to 1.74). However, the most rigorously conducted trial, which was at low risk of bias, did not show any additional benefit of MPFF (RR 0.94; 95% CI 0.73 to 1.22). Since this trial was unpublished, the possibility of publication bias in trials involving flavonoids must be acknowledged. Overall, the quality of reporting of trials on HR was also poor. Pooling three trials, all at unclear risk of bias, involving 279 participants showed a statistically significant effect in favour of HR with respect to number of ulcers healed (RR 1.70; 95% CI 1.24 to 2.34).
Authors' Conclusions:
Although the overall estimate of the number of healed ulcers appeared to show a significant effect in favour of flavonoids (both MPFF and HR), this result needs to be interpreted cautiously, as most of these trials were poorly reported, and so had an unclear risk of bias for randomisation, allocation concealment, blinding and methods for addressing incomplete outcome data. There was also a possibility of publication bias.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Varicose Veins II: Diagnostic Studies and Interprofessional Care
Varicose Veins I: Introduction
Venous Thrombosis I: Introduction
Diabetic Foot Ulcer

